Myriad Genetics, Inc. (MYGN) Stock Analysis

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, October 20, 2026 at 3:45 PM UTC 4 min read

Myriad Genetics' stock experienced a significant surge following the announcement of its $210 million sale of its prenatal testing unit. This strategic divestiture allows the company to streamline operations and focus on its core genetic testing services, potentially enhancing profitability. For investors, this move signals a commitment to improving financial performance and could lead to increased shareholder value in the long term.

Read full article →

Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset

Fri, September 18, 2026 at 7:14 AM UTC 4 min read

Myriad Genetics (MYGN) saw a decline in its stock's fair value following an analyst downgrade and a reset of its guidance. This adjustment indicates potential challenges in the company's growth outlook, which could impact investor confidence and future performance. Investors should be cautious as these developments may signal a more challenging operating environment for Myriad Genetics moving forward.

Read full article →